Enanta Pharmaceuticals (ENTA) Price & Analysis

Compare

189 Followers

ENTA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.09 - $15.34

Previous CloseN/A

Volume330.58K

Average Volume (3M)972.65K

Market Cap

$226.82M

Enterprise Value$164.60M

Total Cash (Recent Filing)$204.11M

Total Debt (Recent Filing)$207.10M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

Nov 17, 2025

EPS Estimate

-1.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.85

Shares Outstanding21,377,922

10 Day Avg. Volume2,574,689

30 Day Avg. Volume972,650

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.70

Price to Sales (P/S)3.24

P/FCF Ratio-2.27

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue2.54

Enterprise Value/Gross Profit2.54

Enterprise Value/Ebitda-2.00

Forecast

1Y Price Target

$18.33

Price Target Upside77.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentIn high-risk patients, zalicapavir showed a compelling signal of faster symptom resolution in a prespecified subgroup.

Financial HealthThe company has cash and marketable securities of $204.1M to fund operations into fiscal 2028, indicating strong financial health.

Pipeline ExpansionEnanta plans to introduce a third immunology program, expanding its pipeline and potential for future growth.

Bears Say

Clinical Trial ResultsThe RSV antiviral zalicapavir showed significant variability in infants and failed in low-risk adult outpatients.

Clinical TrialsENTA missed the primary endpoint but reported very strong data in the HR3 population, as well as the all 13 RSV symptoms for the full zelicapavir.

Enanta Pharmaceuticals News

Enanta upgraded to Buy from Hold at Jefferies

Jefferies analyst Akash Tewari upgraded Enanta (ENTA) to Buy from Hold with a price target of $20, up...

2d ago

ENTA

Enanta upgraded to Buy at Jefferies on higher confidence in RSV antiviral

As previously reported, Jefferies upgraded Enanta (ENTA) to Buy from Hold with a price target of $20, up...

2d ago

ENTA

Enanta 6.5M share Spot Secondary priced at $10.00

The deal size was increased to $65M from $50M and priced at low end of $10.00-$10.50 target range....

3d ago

ENTA

Closing Bell Movers: Nike rallies 4% after earnings beat and guidance

In the opening hour of the evening session, U.S. equity futures are slightly lower, with Dow Industrials off...

3d ago

AIR

COP

Enanta $50M Spot Secondary; price range $10.00-$10.50

JPMorgan and Evercore ISI are acting as joint book running managers for the offering. Published first on TheFly...

3d ago

ENTA

Enanta announces $50M common stock offering

Enanta (ENTA) Pharmaceuticals announced it has commenced an underwritten public offering for $50M of shares of its common...

3d ago

ENTA

Enanta reports ‘positive’ results from Phase 2b study of zelicapavir

Enanta (ENTA) Pharmaceuticals announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate...

5d ago

ENTA

Enanta Pharmaceuticals Announces Public Stock Offering

Enanta Pharmaceuticals ( ($ENTA) ) has issued an update. On September 30, 2025, Enanta Pharmaceuticals announced a public...

2d ago

ENTA

Promising Phase 2b Trial Results for Enanta Pharmaceuticals’ Zelicapavir Boost Buy Rating and $20 Price Target

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Enanta Pharmaceuticals, with...

4d ago

ENTA

Enanta Pharmaceuticals Announces Positive Phase 2b Results

Enanta Pharmaceuticals ( ($ENTA) ) has shared an update. On September 29, 2025, Enanta Pharmaceuticals announced positive topline...

5d ago

ENTA

Enanta Pharmaceuticals Announces Positive Phase 2b RSV Study Results

Enanta Pharmaceuticals ( ($ENTA) ) has shared an update. On September 29, 2025, Enanta Pharmaceuticals announced positive topline...

5d ago

ENTA

Enanta announces passing of CFO Paul Mellet Jr.

Enanta (ENTA) Pharmaceuticals announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul...

1M ago

ENTA

Enanta initiated with a Buy at WestPark Capital

WestPark Capital initiated coverage of Enanta (ENTA) with a Buy rating and $24 price target Published first on...

1M ago

ENTA

Enanta Pharmaceuticals Appoints Interim Financial Officers

An update from Enanta Pharmaceuticals ( ($ENTA) ) is now available. On August 26, 2025, Enanta Pharmaceuticals appointed...

1M ago

ENTA

ENTA FAQ

What was Enanta Pharmaceuticals’s price range in the past 12 months?

Enanta Pharmaceuticals lowest stock price was $4.09 and its highest was $15.34 in the past 12 months.

What is Enanta Pharmaceuticals’s market cap?

Enanta Pharmaceuticals’s market cap is $226.82M.

When is Enanta Pharmaceuticals’s upcoming earnings report date?

Enanta Pharmaceuticals’s upcoming earnings report date is Nov 17, 2025 which is in 44 days.

How were Enanta Pharmaceuticals’s earnings last quarter?

Enanta Pharmaceuticals released its earnings results on Aug 11, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.9 by $0.05.

Is Enanta Pharmaceuticals overvalued?

According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enanta Pharmaceuticals pay dividends?

Enanta Pharmaceuticals does not currently pay dividends.

What is Enanta Pharmaceuticals’s EPS estimate?

Enanta Pharmaceuticals’s EPS estimate is -1.03.

How many shares outstanding does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals has 21,377,922 shares outstanding.

What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?

Enanta Pharmaceuticals reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.9. Following the earnings report the stock price went up 5.701%.

Which hedge fund is a major shareholder of Enanta Pharmaceuticals?

Currently, no hedge funds are holding shares in ENTA

Enanta Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-80.64%

Trailing 12-Months

Asset Growth

-24.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals (ENTA) Earnings & Revenues

Historic Earnings Reports

ENTA Stock 12 Month Forecast

Average Price Target

$18.33

▲(77.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.61,11.716923076923077,12.823846153846153,13.93076923076923,15.037692307692307,16.144615384615385,17.25153846153846,18.358461538461537,19.465384615384615,20.572307692307692,21.67923076923077,22.786153846153844,23.893076923076922,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.61,11.203846153846154,11.797692307692307,12.391538461538461,12.985384615384614,13.579230769230769,14.173076923076923,14.766923076923076,15.360769230769229,15.954615384615384,16.548461538461538,17.14230769230769,17.736153846153847,{"y":18.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.61,10.486153846153845,10.362307692307692,10.238461538461538,10.114615384615384,9.99076923076923,9.866923076923076,9.743076923076924,9.61923076923077,9.495384615384616,9.371538461538462,9.247692307692308,9.123846153846154,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >